Most recent update: Tuesday, October 17, 2017 - 13:13

Bariatric News - Cookies & privacy policy

You are here

vBloc Therapy

EnteroMedics’ vBloc Therapy used for failed gastric sleeve

This first-of-its-kind procedure provides critical insight into patient decision-making in individuals who have already opted to undergo, yet failed, an anatomy-altering or lifestyle-restricting bariatric procedure

EnteroMedics has announced a first-of-its-kind procedure in which the company's vBloc Neurometabolic Therapy was used as an adjunctive treatment in two patients with obesity who failed to achieve sufficient weight loss and diabetes control with their previous gastric sleeve surgeries. Both vBloc procedures were performed at the VA North Texas Health Care System by Dr Sachin Kukreja, Director of Bariatric Surgery.

The patients included two veterans, a 64-year-old male and a 55-year-old female, both with a BMI 35-40, and both suffering from diabetes. Each had lost and maintained significant weight loss with their sleeve gastrectomies, but remained with class 2 obesity and diabetes. Each were offered the option to proceed to duodenal switch, gastric bypass, or vBloc; and both opted for vBloc. Their surgeries were performed without incident, and the patients are both recovering well.

"Patients with obesity who have co-morbid diabetes need to understand the urgent need to achieve weight loss to improve their health," said Kukreja. "For some patients, despite having bariatric surgery like a gastric sleeve, additional measures may be necessary to overcome the many signals driving their obesity. vBloc therapy helps to target the neurologic drive that may provide a barrier to optimum weight loss. vBloc therapy is highly adaptable and can be individualized for each patient to control hunger and provide a feeling of fullness when they most need it. This results in safe, durable weight loss while helping to control co-morbidities. vBloc is also minimally invasive and now, as an adjunctive rescue therapy, will provide an attractive treatment option for patients fighting their obesity after undergoing more invasive surgical treatments."

"This first-of-its-kind procedure provides critical insight into patient decision-making in individuals who have already opted to undergo, yet failed, an anatomy-altering or lifestyle-restricting bariatric procedure," said Dr Scott Shikora, EnteroMedics Executive Vice President and Chief Medical Officer. "Many patients want a solution to their obesity that does not involve the sacrifices associated with more invasive procedures. Because vBloc therapy offers this, it holds the potential to drive greater adoption of bariatric weight loss procedures, improving patient health and reducing the costs associated with treating obesity and its co-morbidities."

Dan Gladney, EnteroMedics President and Chief Executive Officer, said that there are over 100,000 gastrectomies performed in the US each year with up to one-third of patients not achieving or maintaining meaningful weight loss after five years. 

Want more stories like this? Subscribe to Bariatric News!

Bariatric News
Keep up to date! Get the latest news in your inbox.